TY - JOUR
T1 - Avoiding Toxicity With Lung Radiation Therapy
T2 - An IASLC Perspective
AU - International Association for the Study of Lung Cancer Advanced Radiation Technology Committee
AU - Bucknell, Nicholas W.
AU - Belderbos, José
AU - Palma, David A.
AU - Iyengar, Puneeth
AU - Samson, Pamela
AU - Chua, Kevin
AU - Gomez, Daniel
AU - McDonald, Fiona
AU - Louie, Alexander V.
AU - Faivre-Finn, Corinne
AU - Hanna, Gerard G.
AU - Siva, Shankar
N1 - Funding Information:
Disclosures: Dr. Bucknell receives an Australian Government Scholarship, Australia and a research grant from the Royal Australian and New Zealand College of Radiologists, Australia. Drs. Louie, McDonald, and Hanna report receiving honoraria from AstraZeneca, United Kingdom. Dr. Iyengar reports participating in an advisory board from AstraZeneca. Dr. Faivre-Finn reports receiving grants from Elekta and AstraZeneca; consulting fees from AstraZeneca and Merck Sharp & Dohme, United Kingdom; honoraria from AstraZeneca; and payment from participating in an advisory board from AstraZeneca (all payments are made to the institution). Dr. Gomez reports receiving grants from Varian and AstraZeneca; consulting fees from GRAIL, Olympus, and AstraZeneca; honoraria from Varian and MedLearning group; and meeting support from GRAIL. Dr. Chua reports receiving grants from the National Medical Research Council and the Duke–National University of Singapore Medical School; honoraria from AstraZeneca, Peer Voice, University of Hong Kong, and Hong Kong Stereotactic Body Radiation Therapy Study Group; and payment from participating in an advisory board from AstraZeneca. Dr. Chua reports having leadership roles including in the Advanced Radiation Technology Committee, Scientific Committee, Lung Cancer Consortium Singapore, and British Journal of Radiology. Dr. Siva reports receiving grants from Varian, Merck Sharp & Dohme, and Bayer; consulting fees from AstraZeneca and Reflexion; honoraria from AstraZeneca and Reflexion; and meeting support from AstraZeneca. The remaining authors declare no conflict of interest.
Funding Information:
Disclosures: Dr. Bucknell receives an Australian Government Scholarship, Australia and a research grant from the Royal Australian and New Zealand College of Radiologists, Australia. Drs. Louie, McDonald, and Hanna report receiving honoraria from AstraZeneca, United Kingdom. Dr. Iyengar reports participating in an advisory board from AstraZeneca. Dr. Faivre-Finn reports receiving grants from Elekta and AstraZeneca; consulting fees from AstraZeneca and Merck Sharp & Dohme, United Kingdom; honoraria from AstraZeneca; and payment from participating in an advisory board from AstraZeneca (all payments are made to the institution). Dr. Gomez reports receiving grants from Varian and AstraZeneca ; consulting fees from GRAIL, Olympus, and AstraZeneca; honoraria from Varian and MedLearning group; and meeting support from GRAIL. Dr. Chua reports receiving grants from the National Medical Research Council and the Duke–National University of Singapore Medical School; honoraria from AstraZeneca, Peer Voice, University of Hong Kong, and Hong Kong Stereotactic Body Radiation Therapy Study Group; and payment from participating in an advisory board from AstraZeneca. Dr. Chua reports having leadership roles including in the Advanced Radiation Technology Committee, Scientific Committee, Lung Cancer Consortium Singapore, and British Journal of Radiology. Dr. Siva reports receiving grants from Varian, Merck Sharp & Dohme , and Bayer; consulting fees from AstraZeneca and Reflexion; honoraria from AstraZeneca and Reflexion; and meeting support from AstraZeneca. The remaining authors declare no conflict of interest.
Publisher Copyright:
© 2022
PY - 2022/8
Y1 - 2022/8
N2 - Toxicity concerns from thoracic radiation therapy in the treatment of lung cancers have changed substantially over the past few decades. Survival in the treatment of lung cancer has markedly improved and the introduction of advanced radiation and imaging techniques to treatment planning and delivery has made reducing toxicity possible. Phase 3 dose-escalation trials have revealed that excess dose to critical organs within the thorax can negatively impact overall survival. We summarize the existing literature on the known toxicities of thoracic radiation therapy, summarize the technological advances that have made toxicity reduction possible, and provide an overview of emerging technologies and biomarkers that are being evaluated to assess future toxicity reductions.
AB - Toxicity concerns from thoracic radiation therapy in the treatment of lung cancers have changed substantially over the past few decades. Survival in the treatment of lung cancer has markedly improved and the introduction of advanced radiation and imaging techniques to treatment planning and delivery has made reducing toxicity possible. Phase 3 dose-escalation trials have revealed that excess dose to critical organs within the thorax can negatively impact overall survival. We summarize the existing literature on the known toxicities of thoracic radiation therapy, summarize the technological advances that have made toxicity reduction possible, and provide an overview of emerging technologies and biomarkers that are being evaluated to assess future toxicity reductions.
KW - Early-stage lung cancer
KW - Locally advanced lung cancer
KW - Non–small cell lung cancer
KW - Radiation toxicity
KW - Small cell lung cancer
KW - Stereotactic body radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85133298233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133298233&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2022.05.003
DO - 10.1016/j.jtho.2022.05.003
M3 - Review article
C2 - 35649502
AN - SCOPUS:85133298233
SN - 1556-0864
VL - 17
SP - 961
EP - 973
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 8
ER -